Periodic Reporting for period 1 - MITHAML (MITHAML – Exploring the role of Metabolic IntraTumoral Heterogeneity in drug resistance of Acute Myeloid Leukemia in vivo)

Acute Myeloid Leukemia (AML) patient prognosis remains dramatic with a 5-year overall survival of only 28%. However, several new-drugs have been approved by the FDA during the last 2 years. This includes venetoclax (VEN), a selective inhibitor of the anti-apoptotic protein...